Glaxo Smith Kline results, Q4 2024
Net profit, assets, equity and cash flow for Q4 2024, against the same period a year earlier, from the published financial statements.
Net profit68.15 millionEGP · +400.1% vs the same period a year earlier
Total assets3.65 billionEGP · +2.7% vs the same period a year earlier
Shareholders' equity2 billionEGP · +1.5% vs the same period a year earlier
Operating cash flow-188 millionEGP · −155.6% vs the same period a year earlier
In short
- Glaxo Smith Kline's net profit for Q4 2024 was about 68.15 million EGP, up +400.1% from 13.63 million EGP in Q4 2023.
- Total assets at the end of Q4 2024 were about 3.65 billion EGP, and shareholders' equity about 2 billion EGP.
- Operating cash flow for Q4 2024 was negative at 188 million EGP.
Key lines against the same period a year earlier
This periodQ4 2023Change
Net profit68.15 million13.63 million+400.1%
Gross profit282 million468 million−39.7%
Total assets3.65 billion3.56 billion+2.7%
Total liabilities1.66 billion1.59 billion+4.0%
Shareholders' equity2 billion1.97 billion+1.5%
Total liabilities and equity3.65 billion3.56 billion+2.7%
Operating cash flow-188 million337 million−155.6%
Investing cash flow54.37 million205 million−73.5%
Financing cash flow-3.45 million-25.37 million+86.4%
Net change in cash-137 million517 million−126.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy